Immunol Invest . Effect of Chemokine Gene Variants on Covid-19 Disease Severity

[tetano]

Immunol Invest


. 2022 Jun 28;1-10.
doi: 10.1080/08820139.2022.2088383. Online ahead of print.
Effect of Chemokine Gene Variants on Covid-19 Disease Severity


Seydanur Dogan ¹ , Selen Zeliha Mart Komurcu ² , Merve Damla Korkmaz ³ , Ebru Kaya ⁴ , Sevim Yavas ⁵ , Serkan Dogan ⁶ , Hayriye Senturk Ciftci ¹ , Selcuk Dasdemir ¹



Affiliations

• PMID: 35763308
• DOI: 10.1080/08820139.2022.2088383

Abstract

Patients immune phenotype/genotype data may be useful to understand the molecular mechanisms involved in SARS-CoV-2 infection and can contribute to the identify the different levels of disease severity. The roles of chemokines have been reported in the coronavirus-related diseases SARS and MERS and they may likewise play a critical role in the development of the symptoms of COVID-19 disease. We analyzed the association of the MCP-1-A2518 G, SDF-1-3'A, CCR5-delta32, CCR5-A55029 G, CXCR4-C138T and CCR2-V64I gene polymorphisms with COVID-19 severity to further unveil the immunological pathways leading to disease severity and death. Polymerase chain reaction(PCR)/Sanger sequencing analysis was performed for detection of the variations in 60 asymptomatic and 119 severe COVID-19 patients. In our study, we found that the frequencies of MCP-1 of GA genotype and G allele carriers were significantly higher in severe COVID-19 patients than the asymptomatic COVID-19 patients (p < .0001 and p: .005, respectively). However, no significant association was found for any of the other polymorphisms with the severity of COVID-19. Our findings suggest that there is a positive association between MCP-1-A2518 G gene variants with the severity of COVID-19. However, larger studies in different population which will focus on gene expression levels will help us to understand the capability of the mechanism role.

Keywords: COVID-19 severity; Chemokines; MCP-1.